283 related articles for article (PubMed ID: 28445152)
1. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.
Yoo C; Kang J; Kim D; Kim KP; Ryoo BY; Hong SM; Hwang JJ; Jeong SY; Hwang S; Kim KH; Lee YJ; Hoeflich KP; Schmidt-Kittler O; Miller S; Choi EK
Oncotarget; 2017 Jun; 8(24):38592-38601. PubMed ID: 28445152
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
[TBL] [Abstract][Full Text] [Related]
5. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
7. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
[TBL] [Abstract][Full Text] [Related]
8. Incidental Intra-Hepatic Cholangiocarcinoma and Hepatocholangiocarcinoma in Liver Transplantation: A Single-Center Experience.
Serra V; Tarantino G; Guidetti C; Aldrovandi S; Cuoghi M; Olivieri T; Assirati G; De Ruvo N; Magistri P; Ballarin R; Di Benedetto F
Transplant Proc; 2016 Mar; 48(2):366-9. PubMed ID: 27109957
[TBL] [Abstract][Full Text] [Related]
9. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection.
Huang J; Wang X; Zhu Y; Wang Z; Li J; Xu D; Wang S; Li TE; Lu L
J Surg Oncol; 2019 Jan; 119(1):40-46. PubMed ID: 30480811
[TBL] [Abstract][Full Text] [Related]
10. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
11. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
13. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.
Liu TT; You HL; Weng SW; Wei YC; Eng HL; Huang WT
PLoS One; 2015; 10(12):e0145388. PubMed ID: 26684807
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases.
Chu KJ; Lu CD; Dong H; Fu XH; Zhang HW; Yao XP
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):192-9. PubMed ID: 24370644
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
Yang G; Zong H
Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
[TBL] [Abstract][Full Text] [Related]
18. Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center.
Jesper D; Heyn SG; Schellhaas B; Pfeifer L; Goertz RS; Zopf S; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2018 May; 30(5):552-556. PubMed ID: 29280922
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.
Lin ZY; Liang ZX; Zhuang PL; Chen JW; Cao Y; Yan LX; Yun JP; Xie D; Cai MY
BMC Cancer; 2016 Oct; 16(1):792. PubMed ID: 27733196
[TBL] [Abstract][Full Text] [Related]
20. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]